Trial Profile
A Pilot Study to Evaluate the Effects of Switching from Natalizumab to Fingolimod With No Washout in Patients With Multiple Sclerosis (MS)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Feb 2016
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- 24 Feb 2016 New trial record